Compare Neurocrine Biosciences Inc (NBIX) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Western Alliance Bancorporation — how do they compare? Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B), while Western Alliance Bancorporation trades at $76.21 (market cap $8.11B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Western Alliance Bancorporation pays a 2.26% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Western Alliance Bancorporation for 3 Days on average.
| NBIX | WAL | |
|---|---|---|
Market Cap | $14.60B | $8.11B |
Volume | 1,075,694 | 1,479,953 |
Sector | Health | Financials |
52-Week High | $185.50 | $96.08 |
52-Week Low | $123.10 | $66.70 |
Typical Hold Time | 23 Days | 3 Days |
Enterprise Value | $14.61B | $9.63B |
Dividend Yield | — | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Western Alliance Bancorporation (WAL) trades at $74.35, down 2.29% on the day, with a bearish technical outlook despite strong fundamentals. The company maintains robust profitability with 25.43% net income margin and 13.43% ROE, supported by recent earnings beats in Q4 2025 and Q1 2026. Recent developments include the launch of WA VenueX digital asset platform and participation in major financial conferences, while institutional investors show mixed positioning.
WAL presents a compelling value opportunity with attractive valuation multiples (P/E 8.39, P/B 1.07) and strong analyst support (79% buy ratings, $84.33 consensus target). However, near-term risks include the recent Q2 2026 EPS miss, bearish technical indicators, and regulatory uncertainty around Fed policy changes affecting bank asset thresholds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
